N-Terminal Pro-B-Type Natriuretic Peptide in Tricuspid Valve Replacement

被引:2
|
作者
Cheng, Yanmei [1 ]
Ou, Jingsong [2 ]
Tang, Baiyun [1 ]
Wang, Qianqian [3 ]
Liang, Mengya [2 ]
Wang, Zhiping [2 ]
Wu, Zhongkai [2 ]
机构
[1] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Cardiothorac Surg ICU, Guangzhou, Peoples R China
[2] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Cardiac Surg, 58 Zhongshan Rd 2, Guangzhou 510080, Peoples R China
[3] Jishuitan Hosp, Dept Epidemiol & Med Stat, Beijing, Peoples R China
基金
中国国家自然科学基金;
关键词
Tricuspid valve replacement; N-terminal pro-brain natriuretic peptide; Prognosis; VENTRICULAR DIASTOLIC FUNCTION; PROGNOSTIC VALUE; TETRALOGY; ADULTS; DYSFUNCTION; BIOMARKERS; MORTALITY; SURVIVAL; SURGERY; HEART;
D O I
10.1053/j.semtcvs.2020.05.007
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The aim of the present study was to retrospectively investigate the prognostic value of N-terminal pro-brain natriuretic peptide (NT-proBNP) in tricuspid valve replacement (TVR). A total of 73 TVR patients who had NT-proBNP measured on the first postoperative morning during a period of 10 years from February 2008 to December 2018 were included in the study. The endpoint was postsurgery all-cause in-hospital mortality. The outcome-based cut-point optimization was performed using X-tile software. NT-proBNP with the maximum χ2 score and the minimum P value will be used as the optimal cut-point. Kaplan–Meier analysis and log-rank test were adopted to calculate and compare survival rates stratified by tertiles and the cut-point. Predictive capabilities of NT-proBNP were tested using univariable and multivariable Cox regression. Overall, 20 (27.3%) in-hospital deaths occurred. Postsurgery hospital stay was 21 days (interquartile range, 16–32 day). NT-proBNP were divided into low (<1262 pg/mL), medium (1262–4003 pg/mL), and high (≥4003 pg/mL) tertiles. The optimal cut-off point determined using X-tile was 3639 pg/mL. Kaplan–Meier analysis revealed a strong association between worse survival and elevated NT-proBNP expressed as tertiles (log-rank P = 0.002) and stratified by optimal cut point (log-rank P < 0.001). Multivariable Cox survival analysis demonstrated that NT-proBNP was a strong predictor of mortality (logNT-proBNP hazard ratio [HR], 2.11; 95% confidence interval [CI], 1.33–3.37; P = 0.002). In NT-proBNP tertiles model, multivariable Cox survival analysis showed that patients in the medium and high NT-proBNP tertiles had 6.32-fold (adjusted HR, 7.32; 95% CI, 0.76–70.69; P = 0.085) and 16.11-fold (adjusted HR, 17.11; 95% CI, 1.92–152.68, P = 0.011) increased risk for mortality, respectively, compared with patients in the low tertile. Elevated postoperative NT-proBNP level is a potential independent and strong in-hospital postsurgery mortality risk factor in TVR, thus may serve as a useful surrogate marker for risk-stratification. © 2020 Elsevier Inc.
引用
收藏
页码:801 / 810
页数:10
相关论文
共 50 条
  • [31] N-terminal pro-B-type natriuretic peptide as a predictor of repeat coronary revascularization
    Sir, Jung-Ju
    Chung, Woo-Young
    Hwang, Seok-Jae
    Kang, Hyun-Jae
    Cho, Young-Seok
    Koo, Bon-Kwon
    Chae, In-Ho
    Choi, Dong-Ju
    Kim, Hyo-Soo
    Sohn, Dae-Won
    Kim, Cheol-Ho
    Oh, Byung-Hee
    Park, Young-Bae
    Choi, Yun-Shik
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2008, 126 (03) : 322 - 332
  • [32] N-terminal pro-B-type natriuretic peptide in patients with growth hormone disturbances
    Andreassen, Mikkel
    Faber, Jens
    Vestergaard, Henrik
    Kistorp, Caroline
    Kristensen, Lars Ostergaard
    CLINICAL ENDOCRINOLOGY, 2007, 66 (05) : 619 - 625
  • [33] N-TERMINAL PRO-B-TYPE NATRIURETIC PEPTIDE LEVEL IN TYPE 2 DIABETIC PATIENTS
    Vasilkova, Volha
    Mokhort, Tatiana
    Zmailik, Margarita
    Naumenko, Elena
    JOURNAL OF HYPERTENSION, 2016, 34 : E438 - E438
  • [34] Plasma N-terminal pro-B-type natriuretic peptide and mortality in type 2 diabetes
    L. Tarnow
    M.-A. Gall
    B. V. Hansen
    P. Hovind
    H.-H. Parving
    Diabetologia, 2006, 49 : 2256 - 2262
  • [35] Decreasing ratio of plasma N-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide according to age
    Koch, Andreas M. E.
    Rauh, Manfred
    Zink, Stefan
    Singer, Helmut
    ACTA PAEDIATRICA, 2006, 95 (07) : 805 - 809
  • [36] Perioperative B-type Natriuretic Peptide/N-terminal pro-B-type Natriuretic Peptide Next Steps to Clinical Practice
    Fox, Amanda A.
    ANESTHESIOLOGY, 2015, 123 (02) : 246 - 248
  • [37] Direct comparison of B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide in patients with acute dyspnea
    Sabti, Z.
    Murray, K.
    Kozhuharov, N.
    Shrestha, S.
    Schumacher, C.
    Osswald, S.
    Mueller, C. H.
    EUROPEAN HEART JOURNAL, 2017, 38 : 908 - 908
  • [38] N-terminal pro-B-type natriuretic peptide, tricuspid jet flow velocity, and death in adults with sickle cell disease
    Schimmel, Marein
    van Beers, Eduard J.
    van Tuijn, Charlotte F. J.
    Nur, Erfan
    Rijneveld, Anita W.
    Mac Gillavry, Melvin R.
    Brandjes, Dees P. M.
    Schnog, John-John B.
    Biemond, Bart J.
    AMERICAN JOURNAL OF HEMATOLOGY, 2015, 90 (04) : E75 - E76
  • [39] Comparison of Midregional Pro-A-Type Natriuretic Peptide and the N-Terminal Pro-B-Type Natriuretic Peptide for Predicting Mortality and Cardiovascular Events
    van Hateren, Kornelis J. J.
    Alkhalaf, Alaa
    Kleefstra, Nanne
    Groenier, Klaas H.
    de Jong, Paul E.
    de Zeeuw, Dick
    Gans, Rijk O. B.
    Struck, Joachim
    Bilo, Henk J. G.
    Gansevoort, Ron T.
    Bakker, Stephan J. L.
    CLINICAL CHEMISTRY, 2012, 58 (01) : 293 - 297
  • [40] N-terminal Pro-B-Type Natriuretic Peptide and Risk for Diabetes Mellitus and Metabolic Syndrome
    Nicoli, Charles D.
    Long, D. Leann
    Plante, Timothy B.
    Judd, Suzanne E.
    Mcclure, Leslie A.
    Carson, April P.
    Cushman, Mary
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2024, 110 (04): : e1185 - e1193